{"nctId":"NCT00883337","briefTitle":"A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis","startDateStruct":{"date":"2009-04"},"conditions":["Multiple Sclerosis"],"count":324,"armGroups":[{"label":"Teriflunomide 7 mg / 14 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Teriflunomide"]},{"label":"Teriflunomide 14 mg / 14 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Teriflunomide"]},{"label":"IFN-β-1a / 14 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Interferon β-1a","Drug: Teriflunomide"]}],"interventions":[{"name":"Interferon β-1a","otherNames":["Rebif®"]},{"name":"Teriflunomide","otherNames":["HMR1726"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Relapsing form of MS meeting McDonald's criteria for MS diagnosis and Expanded Disability Status Scale \\[EDSS\\] score ≤5.5 at screening visit.\n\nExclusion Criteria:\n\n* Significantly impaired bone marrow function or, significant anemia, leukopenia or thrombocytopenia;\n* Persistent significant or severe infection.\n* Liver function impairment or known history of hepatitis.\n* Use of adrenocorticotrophic hormone \\[ACTH\\] or systemic corticosteroids for 2 weeks prior to randomization.\n* Human immunodeficiency virus \\[HIV\\] positive.\n* Prior use of Rebif®, or prior or concomitant use of other interferons in the 3 months prior to randomization.\n* Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate, mycophenolate, or natalizumab.\n* Pregnant or breast-feeding woman.\n\nExtension criteria:\n\nThe participants who met all the following criteria at the end of the core study period were eligible for enrolment into the open-label extension phase:\n\n* Participants who had not discontinued treatment in the core period and who had a minimum treatment of 48 weeks and completed the EOT visit (Visit 18).\n* Participants who had not met criteria for treatment withdrawal.\n* An informed consent must be obtained in writing from the participant for this open-label extension phase prior to entering and prior to completion of any extension phase procedure.\n* Participants who demonstrated a willingness and ability to roll over to the extension phase with the opportunity to continue treatment on 14 mg/day of teriflunomide under open-label.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Core Treatment Period: Overview of Failures","description":"Failure was defined as the first occurence of confirmed relapse or permanent treatment discontinuation (for any cause) which ever came first. If no events occurred, the participant was considered free of failure.\n\nEach episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in Expanded Disability Status Scale \\[EDSS\\] score or Functional System scores.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]}]},{"type":"PRIMARY","title":"Core Treatment Period: Time to Failure: Kaplan-Meier Estimates of the Rate of Failure at Timepoints","description":"Probability of disability progression at 24, 48 and 96 weeks was estimated using Kaplan-Meier method on the time to failure defined as the time from randomization to failure. Participants free of failure were censored at the date of last treatment.\n\nKaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"24.3","spread":null},{"groupId":"OG002","value":"29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"36.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":null},{"groupId":"OG001","value":"41.1","spread":null},{"groupId":"OG002","value":"44.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Annualized Relapse Rate [ARR] - Poisson Regression Estimates","description":"ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.\n\nTo account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as \"offset\" variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.410","spread":null},{"groupId":"OG001","value":"0.259","spread":null},{"groupId":"OG002","value":"0.216","spread":null}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Change From Baseline in Fatigue Impact Scale (FIS) Total Score","description":"FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.\n\nFIS total score ranges from 0 (no problem) to 160 (extreme problem).\n\nLeast-square means were estimated using a Mixed-effect model with repeated measures \\[MMRM\\] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"2.96"},{"groupId":"OG001","value":"4.10","spread":"3.03"},{"groupId":"OG002","value":"9.10","spread":"3.21"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Treatment Satisfaction Questionnaire for Medication [TSQM] Scores","description":"TSQM version 1.4 is an instrument to assess patients' satisfaction with medication. It consists of 13 questions that cover three dimensions (effectiveness, side effects and convenience) plus a global satisfaction question. Four scores ranging from 0 to 100 (extremely satisfied) are obtained. Least-square means were estimated using a Mixed-effect model with repeated measures \\[MMRM\\] on TSQM score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction as factors).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.25","spread":"2.70"},{"groupId":"OG001","value":"63.13","spread":"2.75"},{"groupId":"OG002","value":"59.30","spread":"2.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.29","spread":"2.31"},{"groupId":"OG001","value":"93.15","spread":"2.34"},{"groupId":"OG002","value":"71.38","spread":"2.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.30","spread":"1.97"},{"groupId":"OG001","value":"89.85","spread":"1.98"},{"groupId":"OG002","value":"61.90","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.29","spread":"2.77"},{"groupId":"OG001","value":"68.82","spread":"2.78"},{"groupId":"OG002","value":"60.98","spread":"2.94"}]}]}]},{"type":"SECONDARY","title":"Core Treatment Period: Overview of Adverse Events [AE]","description":"AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103","spread":null},{"groupId":"OG001","value":"102","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Treatment Period: Overview of AEs","description":"AEs were any unfavourable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Extension Treatment Period: ARR Poisson Regression Estimates","description":"ARR was obtained from the total number of confirmed relapses that occurred during the treatment period divided by the sum of the standardized treatment durations.To account for the different treatment durations among participants, a Poisson Regression Model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as \"offset\" variable; treatment group, region of enrolment and baseline EDSS stratum as covariates).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.236","spread":null},{"groupId":"OG001","value":"0.193","spread":null},{"groupId":"OG002","value":"0.252","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":110},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Alanine aminotransferase increased","Influenza like illness"]}}}